Mosaic ImmunoEngineering Inc. financial data

Symbol
CPMV on OTC
Location
9114 Adams Ave., #202, Huntington Beach, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
PATRIOT SCIENTIFIC CORP (to 11/19/2020)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.93 % -30.7%
Debt-to-equity -104 % +1.59%
Return On Equity 15.7 % -63.4%
Return On Assets -393 % +48.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.24 M shares 0%
Common Stock, Shares, Outstanding 7.24 M shares 0%
Entity Public Float 817 K USD -44.4%
Common Stock, Value, Issued 72 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.24 M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 7.24 M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 325 K USD -63.9%
General and Administrative Expense 884 K USD -39.4%
Operating Income (Loss) -1.21 M USD +48.7%
Nonoperating Income (Expense) 311 K USD -10.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -898 K USD +55.4%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -898 K USD +55.5%
Earnings Per Share, Basic -0.12 USD/shares +57.1%
Earnings Per Share, Diluted -0.12 USD/shares +57.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 65 K USD -48.3%
Assets, Current 79 K USD -46.8%
Assets 79 K USD -46.8%
Accounts Payable, Current 129 K USD +1.21%
Employee-related Liabilities, Current 3.35 M USD +27.6%
Accrued Liabilities, Current 632 K USD +5.05%
Liabilities, Current 4.9 M USD +17.4%
Liabilities 6.23 M USD +14.9%
Retained Earnings (Accumulated Deficit) -8.2 M USD -12.3%
Stockholders' Equity Attributable to Parent -6.15 M USD -16.6%
Liabilities and Equity 79 K USD -46.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -91.1 K USD +47%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 7.24 M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 65 K USD -48.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 3.15 M USD +11.5%
Deferred Tax Assets, Operating Loss Carryforwards 442 K USD -12.4%
Preferred Stock, Shares Authorized 5 M shares 0%
Additional Paid in Capital 2.05 M USD +1.06%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.87 K USD -10%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%